TCTR20180312001.

Study name	Efficacy safety and health‐related quality of life (HRQoL) of cytisine in smoking cessation
Methods	Double‐blind, RCT
Participants	130 participants, 18‐65 years, current smoker > 10 CPD, motivated to quit
Interventions	Cytisine Placebo
Outcomes	PPA rate at 4, 12, 24 and 48 weeks, verified by self‐report and exhaled CO lung function Self‐reported relapse rate QoL
Starting date	01 May 2018
Contact information	Sunee Lertsinudom, 081‐6617237, lsunee@kku.ac.th
Notes	Study funding: Government Pharmaceuticsl Organization, Thailand